← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV21행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCPhase 2
mFOLFOX6 (mFOLFOX6)
TheRas, Inc., d/b/a BBOT (BridgeBi…·HER2
ORR 54%
Overview
Program
mFOLFOX6
Overview
Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Overview
Modality
ADC
Overview
Target
HER2
Overview
Indication
Non-Small Cell Lung Cancer; NSCLC
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
MoA
Mechanism
target trough concentration (C trough ) for an anti-fibroblast growth factor receptor
MoA
Biomarker
biomarkers (neurotensin, superoxide dismutase, interleukin-6), the National Cancer Institute Common Terminolo
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
PD
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
Impact of home-based port infusion versus hospital-based peripheral infusion on anxiety, quality of life, and emergency visits in gastrointestinal cancer: a prospective observational study by the Turkish Oncology Group (TOG).. Home-based chemotherapy via port catheters offers logistical and potential psychological benefits but may pose unique challenges for patients undergoing prolonged regimens s…
Clinical
Primary efficacy
ORR 54%
Clinical
ORR
54%
Clinical
Result source
ClinicalTrials.gov NCT01913639
Clinical
Data Tier / Score
A · 53
Clinical
Program phase
PHASE_2
Clinical
Clinical sync
2026년 7월 9일 (5일 전)